CTC Capital Management’s Pfizer PFE Stock Holding History

CTC Capital Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,000	Closed	-$350K	–	163
2022 Q3	$350K	Buy	+8,000	New	+$389K	0.28%	79

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CTC Capital Management's PFE Position: Q4 2022 in Review

CTC Capital Management sold out of Pfizer (PFE) in Q4 2022, closing a stake of 8,000 shares — an estimated $350K sold.

CTC Capital Management first reported a position in PFE in Q3 2022 and held it in 1 quarter. The position peaked at $350K in Q3 2022. 3,266 funds tracked by Wall St. Rank hold PFE as of Q4 2022.

CTC Capital Management reported no remaining Pfizer position as of Q4 2022 after selling out during the quarter.
CTC Capital Management sold 8,000 Pfizer shares in Q4 2022, an estimated $350K.
CTC Capital Management first reported a position in Pfizer in Q3 2022 and held it in 1 quarter.
CTC Capital Management's Pfizer position peaked at $350K in Q3 2022.
3,266 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.

Based on CTC Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.